Sun Pharmaceutical Industries Limited has announced that its 34th Annual General Meeting (AGM) will be held on Friday, July 31, 2026, at 4:00 p.m. IST via video conferencing. The company has completed the dispatch of the notice for the 34th AGM along with the annual report for the financial year 2025-26 to all shareholders whose email addresses are registered with the Registrar and Transfer Agent, MUFG Intime India Private Limited, or with depository participants. The documents are also available on the company's website and the websites of BSE Limited and the National Stock Exchange of India Limited.

The company has provided a facility for shareholders to cast their votes electronically through remote e-voting. The remote e-voting period commences on Monday, July 27, 2026, at 9:00 a.m. IST and concludes on Thursday, July 30, 2026, at 5:00 p.m. IST. Shareholders holding shares in dematerialized form can log in via the CDSL Easi/Easiest facility or NSDL DeAS facility, while those holding physical shares or non-individual shareholders can access the e-voting website using their DPID/Client ID or Folio Number. Detailed instructions are available under the 'Investor Services' section on the company's website.

Only shareholders whose names are recorded in the Register of Members or the Register of Beneficial Owners as of the cut-off date, Friday, July 24, 2026, are entitled to avail the remote e-voting facility or vote at the AGM. Shareholders who have cast their vote by remote e-voting prior to the meeting may attend the AGM but will not be permitted to vote again. Those who become shareholders after the dispatch of the notice but hold shares as of the cut-off date may generate login credentials by following the guidelines provided on the company's website.

The company has emphasized the importance of updating Know Your Customer (KYC) details for shareholders holding shares in physical form. As per a SEBI circular dated June 10, 2024, shareholders must update their PAN, contact details, nomination, bank account details, and specimen signature. Failure to meet these KYC requirements, excluding the non-submission of a choice of nomination, will result in an inability to receive dividends. Shareholders holding shares in demat form must contact their depository participants to update their details.

In the event of queries or grievances regarding attending the AGM or e-voting, shareholders may refer to the FAQs and e-voting manual available at www.evotingindia.com . They may also contact Mr. Rakesh Dalvi, Senior Manager at Central Depository Services (India) Limited, via email at helpdesk.evoting@cdsindia.com or call the toll-free number 1800 21 09911.

Key Dates for Sun Pharmaceutical Industries Limited 34th AGM

Sun Pharmaceutical Industries Limited reported a strong financial performance for the financial year ended March 31, 2026, with consolidated revenues growing by 11.9% to ₹582,201 million. EBITDA increased by 16.1% to ₹177,314 million, reflecting operational strength and margin expansion, while net profit after minority interest grew by 5% to ₹114,794 million. The company maintained its position as the largest pharmaceutical company in India with an 8.4% market share, according to AIOCD AWACS MAT March 2026 data.

Financial Highlights

The company reported an adjusted net profit after minority interests of ₹124,015 million and increased its net worth to ₹835,701 million. R&D expenditure for the year stood at ₹35,540 million, representing 6.1% of sales. The innovative medicines business accounted for 22% of consolidated sales.

Operational Performance

The India formulation business recorded a 14% increase in sales to ₹192,904 million, contributing 33% of consolidated revenues. This growth was driven by chronic therapies, new product launches, and deeper market reach. The company entered the GLP-1 receptor agonist category in India with the launch of semaglutide under the brand names Noveltreat and Sematrinity. In the US, sales dipped slightly by 0.9% to ₹168,242 million, where growth in innovative medicines offset the decline in the generics business. Emerging markets performed well, supported by innovative medicines and strengthening commercial capabilities, recording an 18.8% sales growth to ₹111,865 million.

The company continued to invest in innovation, bringing two new treatments, LEQSELVI and UNLOXCYT, to market during the year. Sun Pharmaceutical Industries Limited also announced an agreement to acquire Organon to strengthen its global innovative medicines portfolio.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE044A01036/b95f130aea384791.pdf